Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 75

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 75
---
 Uses of Funds The following tables summarize the sources and uses for funding the Business Combination, assuming none of Iris’s outstanding shares of Iris Class A Common Stock are redeemed in connection with the Business Combination.

| Sources of funds                          | ​ | ​ | $ Millions |   |      |   | ​ |
|:------------------------------------------|:--|:--|:-----------|:--|-----:|:--|:--|
| SPAC Cash in Trust                        | ​ | ​ | ​          | $ |  1.9 | ​ | ​ |
| Cash on Balance Sheet                     | ​ | ​ | ​          | ​ |  0.4 | ​ | ​ |
| Private Placement of Common Equity (PIPE) | ​ | ​ | ​          | ​ | 15.0 | ​ | ​ |
| Total Sources of Funds                    | ​ | ​ | ​          | $ | 17.3 | ​ | ​ |

10

TABLE OF CONTENTS

| Uses of funds                 | ​ | ​ | $Millions |   |      |   | ​ |
|:------------------------------|:--|:--|:----------|:--|-----:|:--|:--|
| Loan Payoff                   | ​ | ​ | ​         | $ |  1.5 | ​ | ​ |
| Cash on Balance Sheet         | ​ | ​ | ​         | ​ |  4.7 | ​ | ​ |
| Transaction Fees and Expenses | ​ | ​ | ​         | ​ | 11.1 | ​ | ​ |
| Total Uses of Funds           | ​ | ​ | ​         | $ | 17.3 | ​ | ​ |

The Iris Board’s Reasons for Approving the Business Combination On November 30, 2022, the Iris Board: (i) determined that the Business Combination was advisable to and in the best interests of Iris and its stockholders, (ii) unanimously approved the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination), and (iii) recommended that Iris’s stockholders approve the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination). On November 30, 2022, the Business Combination Agreement was executed by the parties. The Registration Statement was initially declared effective by the SEC on August 9, 2024. On August 16, 2024, Liminatus informed us that TDT, Liminatus’s license partner for the intellectual property and other rights related to GCC (